RxDoctor Payments Data

Joji Urlanda, MD

Nephrology · Naples, FLNPI 1669539409

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 37 payments — averaging $56.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$537
  • Fresenius USA Marketing, Inc.$401
  • Kaneka Medical America LLC$184
  • Akebia Therapeutics Inc$168
  • Bayer$149
  • Amgen$137
  • plus $518 from 6 others

What the payments were for

  • Food & beverage$2,06198%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$328,278
Medicare patients
243
Services billed
2,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide23$54,933
LokelmaSodium Zirconium Cyclosilicate30$43,701
AuryxiaFerric Citrate13$22,936
Sevelamer Carbonate45$15,273
Midodrine Hcl31$3,292
Calcium Acetate22$2,524
Hydralazine Hcl34$950
Nifedipine ErNifedipine14$499
Gabapentin12$360
Metoprolol Succinate19$293
Amlodipine Besylate61$289
Ropinirole Hcl11$232
Carvedilol27$145
Losartan Potassium14$114
Torsemide13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$401$54,93323 claims
AstraZenecaLokelma$537$43,70130 claims
Akebia Therapeutics IncAuryxia$168$22,93613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →